Loading clinical trials...

Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients | Clinical Trials | Clareo Health

COMPLETED

Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients

NCT01466946•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of the study is to understand why Hispanic/Latino patients with lung cancer are diagnosed later than other groups.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Self-identified Hispanic/Latino patients with biopsy-proven primary lung cancer treated at MSKCC, including stages of disease I-IV
•18 years of age or older
•Fluent in English or Spanish
•Patients must reside in the U.S

Exclusion Criteria

•Spanish-surnamed patients who do not self identify as Hispanic/Latino (e.g., Philippines-born individuals)

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

November 1, 2011

Primary Completion Date

February 1, 2016

Completion Date

February 1, 2016

Last Updated

February 11, 2016

Enrollment

ACTUAL participants

Conditions

Lung Cancer

Interventions

semi-structured interviews

BEHAVIORAL

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Magnetic Resonance Imaging of the Lung: Oncological Applications

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)